BioCentury
ARTICLE | Company News

NICE backs narrow Hycamtin use

September 11, 2009 1:48 AM UTC

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Hycamtin topotecan from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) in combination with cisplatin to treat recurrent or stage IVB cervical cancer only in cisplatin-naïve patients. In June, NICE recommended against the use of the topoisomerase inhibitor plus cisplatin for the indication in all groups. In July, GSK asked the agency to consider updated evidence for the cisplatin-naïve group, which the company said at the time has "very limited treatment options" in the final stages of disease. ...